Kevin Sayer Sells 26,759 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,759 shares of the business’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the sale, the insider owned 382,482 shares of the company’s stock, valued at approximately $27,538,704. The trade was a 6.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Trading Down 0.1%

Shares of DXCM stock traded down $0.09 on Tuesday, reaching $72.01. 5,311,632 shares of the stock were exchanged, compared to its average volume of 5,319,043. The stock has a market cap of $27.79 billion, a PE ratio of 30.77, a P/E/G ratio of 1.19 and a beta of 1.40. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The stock has a 50 day moving average price of $63.72 and a 200 day moving average price of $66.09.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the business posted $0.32 earnings per share. DexCom’s revenue was up 15.0% compared to the same quarter last year. Equities research analysts forecast that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Hedge Funds Weigh In On DexCom

Several institutional investors and hedge funds have recently made changes to their positions in the company. Glenmede Trust Co. NA lifted its stake in DexCom by 36.7% in the first quarter. Glenmede Trust Co. NA now owns 394,751 shares of the medical device company’s stock valued at $24,790,000 after buying an additional 105,928 shares in the last quarter. Wellington Grp LLC lifted its stake in DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after buying an additional 475 shares in the last quarter. Janus Henderson Group PLC lifted its stake in DexCom by 32.3% in the first quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock valued at $166,077,000 after buying an additional 645,534 shares in the last quarter. Centaurus Financial Inc. bought a new position in DexCom in the first quarter valued at approximately $943,000. Finally, Tri Locum Partners LP lifted its stake in DexCom by 65.6% in the first quarter. Tri Locum Partners LP now owns 698,158 shares of the medical device company’s stock valued at $43,844,000 after buying an additional 276,558 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on DXCM. Raymond James Financial set a $81.00 price objective on shares of DexCom in a report on Friday, May 1st. Sanford C. Bernstein set a $77.00 target price on DexCom in a report on Friday, May 1st. Weiss Ratings upgraded DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Piper Sandler restated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Finally, Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $82.21.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.